|
|
 |
|
Viewing report
|
|
|
|
Acute Leukemias - Persistent Unmet Needs Confer Significant Commercial Opportunity
Datamonitor, April 2006, Pages: 205
While existing treatment strategies for adult acute leukemia may yield satisfactory remission- induction rates, a major clinical concern is the high rate of disease relapse despite attempts to optimize post-remission consolidation therapy. This is acutely problematic among elderly patients who are frequently unable to tolerate the rigors of more intensive treatment approaches.
Scope of this title:
- Overview of acute leukemias including epidemiology, etiology, disease classification and prognostic variables.
- Current treatment controversies and novel therapies in the developmental pipeline.
- Analysis of trial data, marketing factors and commercial potential for key technologies in clinical development.
- Stakeholder opinions and interview transcripts based on qualitative interviews with key opinion leaders from the US and Europe.
Highlights of this title:
For the innovators of novel and efficacious pharmacotherapy, commercial opportunities within the acute leukemia market are rife. Developers can exploit the high unmet needs that currently prevail in the acute leukemia market by using accelerated approval pathways to expedite market access and drive commercialization
Future drug development approaches will respond to the increased identification of gene mutations and their ensuing proteonomic manifestations. This approach is more likely to address the heterogeneity of acute leukemia and will contribute to the increasing trend of risk-stratified treatment approaches.
Reflecting a greater understanding of disease biology, the enthusiastic pursuit of Flt-3 inhibition in the development of novel acute myeloid leukemia treatment has resulted in already crowded pipeline, with four products challenging for first-to-market status: Cephalons CEP-701, Novartis PKC-412, Millenniums MLN518 and Pfizers SU11248.
Reasons to order your copy:
- Identify the areas of unmet need and clinical controversy in acute leukemia treatment.
- Understand how advancements in acute leukemia prognostication and risk-stratification may shift future treatment paradigms
- Assess opportunities and risks for innovative treatments targeting the acute leukemias.
Customers who bought this item also bought
Acute Myeloid Leukemia: Cytarabine Here to Stay
Drugs of Tomorrow: Leukemia - Chemopotentiators Will Drive Growth in the Acute Leukemia Markets
Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Drug Pipeline Report
Cancer Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia
US patient population for acute myelogenous leukemia ( AML ) forecast for 2000 to 2003, and forecast dollar sales and users of Mylotarg ( CMA 676, gemtuzumab ozogamicin ), a new AML drug, in the US and European Union in each year
Treatment Algorithms 2002: Heart failure - managing chronic and acute patients
Treatment Algorithms 2002: Venous Thromboembolism Acute Therapy
Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth
Pipeline Insight: Acute Stroke: Commercial Risk Offsets High Unmet Need
Analytical Tool - Leukemia Therapeutics & Competitive Insights
Niche Cancers 2001: Acute Myeloid Leukemia
Chronic Myeloid Leukemia - Gleevec resistance is opening a market for synergistic use
|
|
|
|
